Biopharmaceuticals
Recce Pharmaceuticals Ltd. (ASX:RCE) is pioneering the development and commercialization of a new class of antibiotics with broad spectrum activity designed to address the urgent global health problem of antibiotic-resistant superbugs. Recce’s antibiotic’s potency does not diminish even with repeated use. The lead patented candidate, RECCE® 327, has been developed for the treatment of blood infections and sepsis derived from E. coli and S. aureus bacteria — including their superbug forms.
James Graham
Nice Insight/That’s Nice
89 Fifth AvenueFifth FloorNew YorkNY 10003-3020
New York – San Diego – ChicagoLondon – Frankfurt – Shanghai
Nice Insight is the market research division of That’s Nice LLC, the leading marketing agency serving life sciences.